Sparsentan, a medication, may be a potential new treatment option for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disorder that can lead to kidney failure. A University of Minnesota Medical School-led study found that FSGS patients treated with sparsentan showed improved kidney function and displayed significant reductions in proteinuria.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
